-
2024-08-22 / News
3SBio Unveils 2024 Interim Results: Revenue Up 16% YoY, Autoimmune Pipeline Poised for a Promising Phase
-
2024-03-20 / News
3SBio reveals 2023 annual results: Revenue surges by 13.8% year on year, with pipelines to reap the rewards
3SBio will remain steadfast in its role as a national biopharmaceutical leader
-
2023-03-21 / News
3SBio announces 2022 annual results, with revenue rising 7.5% year on year and normalized net profit attributable to parents jumping 25.2%
3SBio is committed to sharpening its focus on refined management and ensuring the healthy developmen...
-
2022-08-24 / News
3SBio announces 2022 interim results, with net profit attributable to owners of the parents continuing to grow despite COVID-19 and cash hitting new record high
with net profit attributable to owners of the parents continuing to grow despite COVID-19 and cash h...
-
2022-03-30 / News
3SBio announces 2021 annual results, with net profit attributable to owns of the parents almost doubling under accelerated growth of diversified businesses
3SBio announces 2021 annual results
-
2021-08-26 / News
3SBio announces 2021 interim results, with strong growth in core businesses and significant progress in clinical development
3SBio maintained strong performance in core businesses, with core products occupying a leading mark...